宫颈腺癌是宫颈癌中最常见的一种类型，其发病率正在增加。宫颈腺癌（CA）的生物行为和治疗结果与鳞状细胞癌（SCC）不同。我们旨在开发一种模型，以预测CA患者的复发和癌症特异性存活（CSS）死亡。131名患者纳入模型开发和内部验证，来自SEER数据库的患者（N = 1679）用于外部验证。多变量Cox比例风险回归分析用于选择无复发生存（RFS）和CSS的预测因子，并构建模型，该模型以两个正射图呈现。使用自助重采样方法对正射图进行内部验证。年龄，FIGO（国际妇产科联合会）分期，肿瘤大小，淋巴转移和浸润深度被确定为RFS的独立预后因子，而年龄，FIGO分期，肿瘤大小和阳性淋巴结数被确定为CSS的独立预后因子。复发模型的正射图预测了2年和5年的RFS，调整后的C统计指标为75.41%和74.49%。另一个正射图预测了2年和5年的CSS，在内部验证后的调整后的C统计指标为83.22%和83.31%，在外部验证后为68.6%和71.33%。我们基于静态正射图或在线计算器开发并验证了两个有效的正射图，可以帮助临床医生量化早期CA患者复发和死亡的风险。© 2023作者。

Cervical adenocarcinoma is one of the most common types of cervical cancer and its incidence is increasing. The biological behavior and treatment outcomes of cervical adenocarcinoma (CA) differ from those of squamous cell carcinoma (SCC). We sought to develop a model to predict recurrence and cancer-specific survival (CSS) deaths in CA patients.131 patients were included in model development and internal validation, and patients from the SEER database (N = 1679) were used for external validation. Multivariable Cox proportional hazards regression analysis was used to select predictors of relapse-free survival (RFS) and CSS and to construct the model, which was presented as two nomograms. Internal validation of the nomograms was performed using the bootstrap resampling method.Age, FIGO (International Federation of Gynecology and Obstetrics) stage, size of the tumor, lymph metastasis and depth of invasion were identified as independent prognostic factors for RFS, while age, FIGO stage, size of the tumor and number of positive LNs were identified as independent prognostic factors for CSS. The nomogram of the recurrence model predicted 2- and 5-year RFS, with optimism adjusted c-statistic of 75.41% and 74.49%. Another nomogram predicted the 2- and 5-year CSS with an optimism-adjusted c-statistic of 83.22% and 83.31% after internal validation; and 68.6% and 71.33% after external validation.We developed and validated two effective nomograms based on static nomograms or online calculators that can help clinicians quantify the risk of relapse and death for patients with early-stage CA.© 2023. The Author(s).